Menu
No results found.
Weekly Share Price & Valuation Overview
Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. In addition, the company offers patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety, bioequivalence, and third-party training services, as well as chemistry, management, and controls services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 58.14B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 64.50B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 6.51B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 2.09B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY 1.06B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 7.54
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.39
- Shares Outstanding
- 737.90M
- Float Shares
- 616.01M
- Implied Shares Outstanding
- 869.41M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
11.27%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
16.26%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
32.06%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
5.16%
- ROA Return on assets: net income ÷ total assets.
-
1.80%
- ROE Return on equity: net income ÷ shareholder equity.
-
1.01%
- Revenue Growth Year-over-year revenue growth.
-
-5.80%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-29.60%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-29.60%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.56
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.13
- Total Cash Cash and equivalents.
- CNY 1.68B
- Total Debt Short + long-term interest-bearing debt.
- CNY 3.05B
- Net Debt Total debt − cash (negative = net cash).
- CNY 1.38B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 2.88
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 1.15B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY 482.27M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
17.68%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
7.41%
- Cash Conversion (OpCF/EBITDA)
- 1.09
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.